Halozyme Therapeutics ( HALO )

Phase 1

Clinical Trials (1)

NCT00435604A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase

Phase 1

PEGPH20

NSCLC

Phase 1

Clinical Trials (1)

NCT02563548A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Phase 1

PEGPH20

Solid Tumor

Phase 1

Clinical Trials (1)

NCT01170897Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Phase 1

SC HYLENEX and Ceftriaxone

Phase 1

Clinical Trials (1)

NCT00493220Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration

Phase 1

Recombinant human hyaluronidase PH20

Risk Factors for or a Diagnosis of Osteoporosis

Phase 1

Clinical Trials (1)

NCT00979875A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Phase 1

rHuPH20

Phase 1

Clinical Trials (2)

NCT05625399A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Phase 3

NCT00807963Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Insulin aspart

Phase 1

Clinical Trials (1)

NCT01275131Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Phase 1

PEGPH20

Solid Tumor

Phase 1

Clinical Trials (1)

NCT00834704Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Phase 1

Ondansetron

Phase 1

Clinical Trials (1)

NCT01572012Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Phase 1

Cohort 1: bococizumab 150 mg + rHuPH20

Superficial Bladder Cancer

Phase 1

Clinical Trials (1)

NCT02667223Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Phase 1

Chemophase

Phase 1

Clinical Trials (1)

NCT00782587Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer

Phase 1

PEGylated recombinant human hyaluronidase PH20

Non-small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT02346370A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

Phase 1

Insulin Lispro

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT00862849Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Phase 1

rHuPH20

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT00803972Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Phase 1

PEGPH20

Cholangiocarcinoma Non-resectable

Phase 1

Clinical Trials (1)

NCT03267940Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Phase 1

Gemcitabine

Stage IV Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT01453153Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Phase 1/2

PEGPH20

Metastatic Pancreatic Adenocarcinoma

Phase 1/2

Clinical Trials (1)

NCT01959139S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Phase 1/2

Mitomycin C

Bladder Cancer

Phase 1/2

Clinical Trials (1)

NCT00318643Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Phase 1/2

5-Fluorouracil

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Phase 1/2

Clinical Trials (1)

NCT03281369A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2

Eribulin mesylate

Metastatic Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT02753595Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2

Insulin lispro

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT01194245Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Phase 2

PEGPH20

Metastatic Pancreatic Cancer

Phase 2

Clinical Trials (1)

NCT01839487PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Phase 2

PEGPH20

Pancreatic Ductal Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT03634332Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2

Pegvorhyaluronidase alfa

Pancreatic Ductal Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT04134468MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Phase 2

CINRYZE with rHuPH20

Hereditary Angioedema

Phase 2

Clinical Trials (1)

NCT01426763A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Phase 2

Insulin lispro

Diabetes Mellitus, Type II

Phase 2

Clinical Trials (1)

NCT01194258Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Phase 2

Atezolizumab

Pancreatic Ductal Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT03979066Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Phase 2

Humalog

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT00774800Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Phase 2

Insulin Lispro

Phase 2

Clinical Trials (1)

NCT00883558Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Phase 2

Humalog

Diabetes Mellitus, Type 2

Phase 2

Clinical Trials (1)

NCT00916357Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 2

rHuPH20

Dermatitis, Allergic Contact

Phase 2

Clinical Trials (1)

NCT00928447Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Phase 2

Biological: PEGylated Recombinant Human Hyaluronidase

Pancreatic Ductal Carcinoma

Phase 3

Clinical Trials (1)

NCT02715804A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Phase 3

Hylenex

Pain

Phase 3

Clinical Trials (1)

NCT00593281INFUSE Morphine Study

Phase 3

Testosterone enanthate

Hypogonadism, Male

Phase 3

Clinical Trials (1)

NCT0668908552 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Phase 3

Rapid Acting insulin with pre-treatment of rHuPH20

Phase 4

Clinical Trials (1)

NCT03662334A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Phase 4

Subcutaneous HYLENEX

Phase 4

Clinical Trials (1)

NCT01116102Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Phase 4

hylenex-facilitated subcutaneous Lactated Ringer's infusion

Phase 4

Clinical Trials (1)

NCT00807885Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

Phase 4

hyaluronidase

Phase 4

Clinical Trials (1)

NCT00477152Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children

Phase 4

Sham Injection

Phase 4

Clinical Trials (1)

NCT01526733Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Phase 4

Oral rehydration fluid

Phase 4

Clinical Trials (1)

NCT01120431Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)

Phase 4

Hylenex

Phase 4

Clinical Trials (1)

NCT00311519A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

Phase 4

recombinant human hyaluronidase

Phase 4

Clinical Trials (1)

NCT00656370Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Phase 4

large protein molecule

Rheumatoid Arthritis

Phase 4

Clinical Trials (1)

NCT00369187Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase

Phase 4

recombinant human hyaluronidase

Phase 4

Clinical Trials (1)

NCT00773175Subcutaneous Rehydration Compared to Intravenous Rehydration

Phase 4

Commercial Hylenex® recombinant